Drug-induced Osteoporosis: Beyond Glucocorticoids

Overview

Journal Curr Rheumatol Rep

Publisher Current Science

Specialty Rheumatology

Date 2008 May 8

PMID 18460264

Citations 7

Authors

Karine Briot

Christian Roux

Affiliations

Soon will be listed here.

Abstract

To prevent osteoporotic fractures, it is important to identify patients at high risk of fracture by assessing risk factors such as underlying diseases and drugs. Prior and current use of oral corticosteroids is strongly associated with increased fracture risk, but other medications could be involved and should be assessed as part of the optimal care of patients at risk of osteoporosis. Strong evidence points to gonadotropin-releasing hormone agonists, aromatase inhibitors, and antiepileptic drugs. Further studies are necessary to confirm the deleterious effect of other treatments on bone.

Citing Articles

Risk factors and epidemiological profile of hip fractures in Indian population: A case-control study.

Ahuja K, Sen S, Dhanwal D Osteoporos Sarcopenia. 2019; 3(3):138-148.

PMID: 30775519 PMC: 6372827. DOI: 10.1016/j.afos.2017.08.097.

Long Non-coding RNAs: A New Regulatory Code for Osteoporosis.

Wu Q, Li X, Miao Z, Ye J, Wang B, Zhang F Front Endocrinol (Lausanne). 2018; 9:587.

PMID: 30349507 PMC: 6186991. DOI: 10.3389/fendo.2018.00587.

Dental implants in Sjögren's syndrome patients: A systematic review.

Almeida D, Vianna K, Arriaga P, Moraschini V PLoS One. 2017; 12(12):e0189507.

PMID: 29240793 PMC: 5730117. DOI: 10.1371/journal.pone.0189507.

Assessment of bone metabolism and biomechanical properties of the femur, following treatment with anastrozole and letrozole in an experimental model of menopause.

Boutas I, Pergialiotis V, Salakos N, Korou L, Mitousoudis A, Kalampokas E Oncol Lett. 2017; 14(3):3494-3502.

PMID: 28943895 PMC: 5592877. DOI: 10.3892/ol.2017.6596.

Impaired skeletal health and neuromuscular function among amphetamine users in clinical treatment.

Mosti M, Flemmen G, Hoff J, Stunes A, Syversen U, Wang E Osteoporos Int. 2015; 27(3):1003-1010.

PMID: 26501558 DOI: 10.1007/s00198-015-3371-z.

References

Rejnmark L, Vestergaard P, Heickendorff L, Andreasen F, Mosekilde L . Loop diuretics increase bone turnover and decrease BMD in osteopenic postmenopausal women: results from a randomized controlled study with bumetanide. J Bone Miner Res. 2005; 21(1):163-70. DOI: 10.1359/JBMR.051003. View

Rajgopal R, Bear M, Butcher M, Shaughnessy S . The effects of heparin and low molecular weight heparins on bone. Thromb Res. 2007; 122(3):293-8. DOI: 10.1016/j.thromres.2006.10.025. View

Hubbard R, Farrington P, Smith C, Smeeth L, Tattersfield A . Exposure to tricyclic and selective serotonin reuptake inhibitor antidepressants and the risk of hip fracture. Am J Epidemiol. 2003; 158(1):77-84. DOI: 10.1093/aje/kwg114. View

Coleman R, Banks L, Girgis S, Kilburn L, Vrdoljak E, Fox J . Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study. Lancet Oncol. 2007; 8(2):119-27. DOI: 10.1016/S1470-2045(07)70003-7. View

Howell A, Cuzick J, Baum M, Buzdar A, Dowsett M, Forbes J . Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet. 2005; 365(9453):60-2. DOI: 10.1016/S0140-6736(04)17666-6. View

Omdahl J, Morris H, May B . Hydroxylase enzymes of the vitamin D pathway: expression, function, and regulation. Annu Rev Nutr. 2002; 22:139-66. DOI: 10.1146/annurev.nutr.22.120501.150216. View

Greenspan S, GREENSPAN F . The effect of thyroid hormone on skeletal integrity. Ann Intern Med. 1999; 130(9):750-8. DOI: 10.7326/0003-4819-130-9-199905040-00016. View

Minaur N, Kounali D, Vedi S, Compston J, Beresford J, Bhalla A . Methotrexate in the treatment of rheumatoid arthritis. II. In vivo effects on bone mineral density. Rheumatology (Oxford). 2002; 41(7):741-9. DOI: 10.1093/rheumatology/41.7.741. View

Caraballo P, Heit J, Atkinson E, Silverstein M, OFallon W, Castro M . Long-term use of oral anticoagulants and the risk of fracture. Arch Intern Med. 1999; 159(15):1750-6. DOI: 10.1001/archinte.159.15.1750. View

10.

Ensrud K, Blackwell T, Mangione C, Bowman P, Bauer D, Schwartz A . Central nervous system active medications and risk for fractures in older women. Arch Intern Med. 2003; 163(8):949-57. DOI: 10.1001/archinte.163.8.949. View

11.

Rejnmark L, Vestergaard P, Mosekilde L . Fracture risk in users of oral anticoagulants: a nationwide case-control study. Int J Cardiol. 2006; 118(3):338-44. DOI: 10.1016/j.ijcard.2006.07.022. View

12.

Wilting I, de Vries F, Thio B, Cooper C, Heerdink E, Leufkens H . Lithium use and the risk of fractures. Bone. 2007; 40(5):1252-8. DOI: 10.1016/j.bone.2006.12.055. View

13.

Vestergaard P, Rejnmark L, Mosekilde L . Proton pump inhibitors, histamine H2 receptor antagonists, and other antacid medications and the risk of fracture. Calcif Tissue Int. 2006; 79(2):76-83. DOI: 10.1007/s00223-006-0021-7. View

14.

Monegal A, Navasa M, Guanabens N, Peris P, Pons F, Martinez de Osaba M . Bone mass and mineral metabolism in liver transplant patients treated with FK506 or cyclosporine A. Calcif Tissue Int. 2001; 68(2):83-6. DOI: 10.1007/BF02678145. View

15.

Cohen O, Rais T, Lepkifker E, Vered I . Lithium carbonate therapy is not a risk factor for osteoporosis. Horm Metab Res. 1998; 30(9):594-7. DOI: 10.1055/s-2007-978939. View

16.

Diamond T, Higano C, Smith M, Guise T, Singer F . Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer. 2004; 100(5):892-9. DOI: 10.1002/cncr.20056. View

17.

Watanabe S, Takeuchi Y, Fukumoto S, Fujita H, Nakano T, Fujita T . Decrease in serum leptin by troglitazone is associated with preventing bone loss in type 2 diabetic patients. J Bone Miner Metab. 2003; 21(3):166-71. DOI: 10.1007/s007740300026. View

18.

Sato Y, Kondo I, Ishida S, Motooka H, Takayama K, Tomita Y . Decreased bone mass and increased bone turnover with valproate therapy in adults with epilepsy. Neurology. 2001; 57(3):445-9. DOI: 10.1212/wnl.57.3.445. View

19.

Halbreich U, Rojansky N, Palter S, HRESHCHYSHYN M, Kreeger J, Bakhai Y . Decreased bone mineral density in medicated psychiatric patients. Psychosom Med. 1995; 57(5):485-91. DOI: 10.1097/00006842-199509000-00011. View

20.

Michaelson M, Kaufman D, Lee H, McGovern F, Kantoff P, Fallon M . Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol. 2007; 25(9):1038-42. PMC: 3047397. DOI: 10.1200/JCO.2006.07.3361. View